DRUG USAGE ANALYSIS AND HEALTH CARE RESOURCES CONSUMPTION IN PATIENTS WITH RHEUMATOID ARTHRITIS

Author(s)

Degli Esposti L1, Sangiorgi D1, Calandriello M2, Buda S1
1CliCon Srl, Ravenna, Italy, 2HE OR Unit - Bristol-Myers Squibb S.r.l., Rome, Italy

OBJECTIVES To prevent irreversible joint damage in rheumatoid arthritis (RA), biological drugs have been developed; when insufficient response is observed, the initial dosage could be increased (dose escalation). The aim of the study was to assess dose escalation among different therapeutic strategies and associated health care resources use. METHODS An observational retrospective cohort analysis based on 3 Local Health Units administrative databases was conducted. Patients who filled at least one prescription for biologic agents with a diagnosis of RA between 01/01/2009-31/12/2011 (enrolment period) were included. Patients were followed-up for 12 months and characterized on the basis of  the previous 12 months. Dose escalation and cost of illness were calculated on naïve patients (patients with no prior prescriptions of the index biologic); dose escalation was defined as having ≥2 consecutive claims with an average weekly dose 130% greater than the initial average weekly dose. RESULTS

Conference/Value in Health Info

2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands

Value in Health, Vol. 17, No. 7 (November 2014)

Code

PMS6

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×